Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-BoB: M6620 and Avelumab in DDR Deficient Advanced Solid Tumors
NCT04266912Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of berzosertib and avelumab in solid tumor (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Mar 2020; status: active, not recruiting.
02
Drugs
berzosertibavelumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04266912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04266912.